Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Goodwill & Intangibles: 2018-2024

Historic Goodwill & Intangibles for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $23.9 million.

  • BridgeBio Pharma's Goodwill & Intangibles rose 17.41% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year increase of 17.41%. This contributed to the annual value of $23.9 million for FY2024, which is 9.09% down from last year.
  • As of FY2024, BridgeBio Pharma's Goodwill & Intangibles stood at $23.9 million, which was down 9.09% from $26.3 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Goodwill & Intangibles peaked at $44.9 million during FY2021, and registered a low of $23.9 million during FY2024.
  • Its 3-year average for Goodwill & Intangibles is $26.3 million, with a median of $26.3 million in 2023.
  • Data for BridgeBio Pharma's Goodwill & Intangibles shows a maximum YoY crashed of 36.10% (in 2022) over the last 5 years.
  • BridgeBio Pharma's Goodwill & Intangibles (Yearly) stood at $44.9 million in 2021, then slumped by 36.10% to $28.7 million in 2022, then decreased by 8.33% to $26.3 million in 2023, then declined by 9.09% to $23.9 million in 2024.